comparemela.com

Latest Breaking News On - Seriesx preferred stock - Page 3 : comparemela.com

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5. | December 27, 2022

Catalyst Biosciences, Inc : Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5

Note 2 – Financial Condition, Going Concern and Management Plans

Note 2 – Financial Condition, Going Concern and Management Plans
insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.

Note 2 – Financial Condition, Going Concern and Management Plans

Each Series D Unit will have a purchase price of $1.00 per Unit, with each Unit consisting of one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share, one warrant to purchase 2.1 shares of the Company's Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant to purchase 2.1 shares of Common.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.